A nemia is frequent among critically ill patients. Around 60% of the critically ill suffer from anemia upon intensive care unit admission. Anemia is associated with increased length of stay, higher morbidity, and mortality (1, 2) . The prevalence and severity of anemia upon discharge from the intensive care unit are also high, concerning up to 80% of the patients (3) . Correcting anemia may thus be highly beneficial. Nowadays, blood transfusion is less frequent, as recommended transfusion thresholds have been decreased (3) (4) (5) . There is a need to better understand the causes of anemia in this setting and to consider additional therapeutic options.
The pathophysiology of anemia of the critically ill is complex. The two main factors leading to iron deficiency are inflammation and blood loss (4, 6) . Inflammation occurs in virtually all critically ill patients. Anemia of the critically ill is therefore considered as an anemia of inflammation (7), characterized by iron-restricted erythropoiesis with iron being diverted from the circulation and stored inside macrophages (8) . Blood withdrawal is also a major cause of anemia during the intensive care unit stay, with a median blood loss of 128 mL per day, representing a daily iron loss of about 64 mg (1, 9, 10) . Finally, iron deficiency is also common in critically ill patients, affecting around one third of all patients (11) (12) (13) . Thus, iron may be considered as an option for treating anemia in critically ill patients (6, 14, 15) . This option is supported by the recent increase in knowledge on the regulation of iron metabolism.
Indeed, the discovery of hepcidin, the main regulator of iron metabolism, has opened up new therapeutic possibilities for critically ill anemic patients (6) . Hepcidin expression is known to be highly inducible by inflammation and fully suppressed by increased bone marrow erythropoiesis. Using a mouse model mimicking critical care anemia, we have shown that stimulation of erythropoiesis by phlebotomy-induced iron deficiency may dominate over inflammation for hepcidin regulation (16) . In other words, in this model, despite inflammation, iron could be mobilized from the storage compartment and used for erythropoiesis. These findings were confirmed in two other animal models where erythropoiesis stimulation through blood withdrawal or Objective: Anemia is common in critically ill patients, due to inflammation and blood loss. Anemia can be associated with iron deficiency and low serum hepcidin levels. However, iron administration in this setting remains controversial because of its potential toxicity, including oxidative stress induction and sepsis facilitation. The objective of this work was to determine the efficacy and toxicity of iron administration using a mouse model mimicking critical care anemia as well as a model of acute septicemia.
Design: Prospective, randomized, open label controlled animal study.
Setting: University-based research laboratory.
Subjects: C57BL/6 and OF1 mice.
Interventions: Intraperitoneal injection of zymosan inducing generalized inflammation in C57BL/6 mice, followed in our full model by repeated phlebotomies. A dose equivalent to 15 mg/kg of ferric carboxymaltose was injected intravenously on day 5. To assess the toxicity of iron in a septicemia model, OF1 mice were simultaneously injected with iron and different Escherichia coli strains.
Measurements and Main Results:
To investigate the effect of iron on oxidative stress, we measured reactive oxygen species production in the blood using luminol-amplified chemiluminescence and superoxide dismutase 2 messenger RNA levels in the liver. These markers of oxidative stress were increased after iron administration in control mice but not in zymosan-treated mice. Liver catalase messenger RNA levels decreased in iron-treated control mice. Iron administration was not associated with increased mortality in the septicemia model or in the generalized inflammation model. Iron increased hemoglobin levels in mice fed with a low iron diet and subjected to phlebotomies and zymosan 2 wks after treatment administration.
Conclusions: Adverse effects of intravenous iron supplementation by ferric carboxymaltose seem to be minimal in our animal models. Furthermore, iron appears to be effective in correcting anemia, despite inflammation. Studies of efficacy and safety of iron in critically ill patients are warranted. (Crit Care Med 2012;  40: 2141-2148) KEY WORDS: anemia; critical care; iron; mice; oxidative stress; septicemia erythropoietin treatment overrode inflammation for hepcidin regulation and allowed the mobilization of tissue iron (17, 18) , and by the observation of low hepcidin levels in some critically ill patients (11) .
Unfortunately, iron may also be toxic for critically ill patients. Iron has the ability to donate electrons and may induce oxidative stress through the Fenton reaction. Iron may also facilitate infection and sepsis because it is an essential element for all living organisms, including pathogens (19, 20) . Indeed, high doses of iron have been shown to increase mortality in a mouse model of sepsis (21) .
To address this controversy, we designed a study evaluating the efficacy and toxicity of intravenous iron supplementation in mice in an inflammatory context, with or without iron deficiency. We assessed short-term toxicity of iron supplementation in both generalized inflammation and septicemia mouse models. Furthermore, we assessed long-term efficacy of iron supplementation in a mouse model of critical care anemia (16) .
MATERIALS AND METHODS

Animals.
Mice were cared for in accordance with criteria outlined in the European Convention for the Protection of Laboratory Animals. The study received approval from the local authorities. Before use, animals were allowed to acclimatize for at least 3 days. Animals were maintained in a temperature and light-controlled environment and were given free access to tap water and normal iron diet (standard laboratory mouse chow, AO3; SAFE, Augy, France) unless otherwise specified. All reagents and compounds were obtained from Sigma, St. Quentin Fallavier, France, unless otherwise specified.
Zymosan-Induced Generalized Inflammation Model, With or Without Phlebotomies. The zymosan-induced generalized inflammation model (ZIGI) induces a septic shock-like syndrome in mice, leading to multiple organ dysfunctions (22) . In this model, we used 8 to 10-wk-old C57BL/6 male mice, weighing 20-25 g (Centre d'Elevage Janvier, Le Genest St Isle, France). Because early mortality dramatically increased, most likely due to changing conditions in our central animal facility, we introduced minor modifications to the initial model (i.e., a reduction in zymosan A dose) (16) . Inflammation was first induced by an intraperitoneal injection of 40 mg of Escherichia coli O128-B12 lipopolysaccharide diluted in 200 mL saline solution, followed by an intraperitoneal injection of 10 mg of zymosan A diluted in 500 mL saline 3 days later. The lipopolysaccharide injection prevents an excessive response to zymosan A, by activating the immune system, so that the ZIGI model constitutes a model of chronic inflammation. The day of zymosan injection is referred to as day 1. No injections were performed on the control animals.
The critical care anemia model consists of the combination of a low iron diet and phlebotomies in mice previously treated by lipopolysaccharide and zymosan A. Mice were provided with an iron-depleted diet (C1038, Genestil, Royancourt, France) starting 4 wks prior to zymosan administration and maintained during the whole experiment.
Phlebotomies were performed by withdrawal of 250-300 mL of blood from the orbital sinus with a calibrated heparinized capillary tube on days 1, 2, and 4, as previously described (16) . Blood obtained on day 4 was processed in the hematology laboratory for determination of hematological indices.
C57BL/6 mice received 0.3 mg of elemental iron in the form of Ferric carboxymaltose (ferric carboxymaltose; Ferinject, Vifor pharma, Fribourg, Switzerland) diluted in 100 mL of saline on day 5 by intravenous injection by the retro-orbital route under light-inhaled isoflurane (Belamont, Paris, France) anesthesia (23) . Control mice received 100 mL of saline by the same route. The 0.3 mg dose of ferric carboxymaltose was chosen because it is equivalent to 15 mg iron/kg body weight, which is the maximum dose of ferric carboxymaltose that may be given in one shot to human beings. Furthermore, this dose covered the estimated iron loss resulting from repeated blood withdrawals (around 0.23-0.28 mg). Mice were killed either 4 hrs later for short-term experiments or on day 19 (i.e., 2 wks after iron injection) for long-term experiments. A total of 55 mice divided into four groups were used for the short-term experiments. Eighteen of these mice died within 4 days of zymosan administration, leaving 37 mice alive, which were divided into four groups of 8-11 animals. A total of 51 mice divided into five groups of 5-15 animals were used for the long-term experiments.
Septicemia Mouse Model. The septicemia mouse model was performed using 14-16 g OF1 female mice (Charles River, L'Arbresle, France), as previously described (24) . Briefly, E. coli strains were grown on Luria-Bertani agar for 24 hrs. One colony was then picked up and grown overnight in a Luria-Bertani broth at 37°C. After two washes in saline, bacteria were diluted to the chosen inoculum. E. coli inoculum was controlled for each experiment by serial plating. OF1 mice were simultaneously given an intravenous injection of 0.2 mg (equivalent to 15 mg iron/kg body weight) ferric carboxymaltose diluted in 100 mL of saline or saline alone, and a subcutaneous injection of 10 6 , 10 7 , or 10 8 colony forming units (CFU) of the bacteria diluted in 200 mL of saline. Mortality was assessed during the following week. In this model, E. coli natural isolates inoculated at 10 8 CFU are either "killer" (>90% of inoculated mice killed) or "nonkiller" (<10% of inoculated mice killed), and very few strains have intermediary lethality (25) . In order to observe increased mortality rates after iron administration in this model, we chose two bacterial strains with intermediate levels of virulence in mice (IAI76 and IAI78) (24) and modulated the inoculum to obtain between 0% and 50% of inoculated mice killed. These two strains were isolated from urinary tract infections, belong to the B2 phylogenetic group associated with extraintestinal virulence, and bear various virulence determinants including the iron capture systems yersiniabactin and iron (IAI76) and yersiniabactin and aerobactin (IAI78) (25) . Each experiment was conducted on two groups of 25 mice. Both groups received the same bacterial strain at the same concentration; the first group additionally received saline whilst the second group received ferric carboxymaltose.
Specimen Collection. On the day the mice were killed, they were weighed. Blood was collected by puncture of the orbital sinus as for phlebotomy (see above), and the heparinized sample was sent to the hematology laboratory for determination of hematologic indices using a Sysmex XE 2100 automate (Roche Diagnostics, Meylan, France). Mice were then killed by cervical dislocation. The abdomen was opened; the liver and spleen were removed. Samples of liver and spleen were aseptically collected and immediately frozen in liquid nitrogen and stored at 280°C.
Whole Blood Chemiluminescence. Phagocyte stimulation activates the nicotinamide adenine dinucleotide phosphate oxidase-2, which produces superoxide anions and generates other reactive oxygen species, such as hydrogen peroxide. This phagocyte function can be evaluated by the luminol-amplified chemiluminescence technique, as previously described (26) . Briefly, 2.5 mL of freshly isolated whole blood was resuspended in 0.5 mL Hank's buffered salt solution containing 10 mM luminol and 5 units of horseradish peroxidase, and was left at room temperature in the chamber of the luminometer (Berthold-Biolumat LB937) and allowed to stabilize. After a baseline reading, cells were stimulated with 10 26 M of formyl-MetLeu-Phe. Changes in chemiluminescence were measured over a 15-min period. The peak of chemiluminescence after formyl-Met-Leu-Phe stimulation is reported. Peaks were normalized by the neutrophil blood count, and determined by blood smear examination and by the peak value of chemiluminescence after formyl-Met-Leu-Phe stimulation of control animals measured on the same day.
Determination of Advanced Oxidation Protein Products. Protein oxidation was measured in plasma separated from blood by determining the advanced oxidation protein products (AOPP) level spectrophotometrically (27) . Briefly, 0.1 mL of plasma diluted 1/10 in phosphate buffered saline was mixed with 5 mL of acetic acid and 2.5 mL of 1.16 M potassium iodide in test tubes. The absorbance of the reaction mixture was read at 340 nm. 0.1 mL of 0-100 mmol/L chloramine T was added in standard tubes. The absorbance of chloramine T was linear between 0 and 100 mmol/L.
RNA Extraction and Quantitative Real Time-Polymerase Chain Reaction. Total RNA was extracted from livers using the RNA plus Extraction Solution Kit (MP Biomedicals SA, Ilkrich, France), according to the manufacturer's instruction. The purity and yield of total RNA were determined spectrophotometrically. The integrity of ribosomal RNA bands (18S and 28S) was checked on agarose gel electrophoresis. Single-strand complementary DNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen Life Technologies, Cergy-Pontoise, France). Real-time polymerase chain reaction quantification of transcripts was performed in 20 mL reactions using the SYBER green I master mix (Roche Diagnostics, Mannheim, Germany), 10 pmol of forward (Fwd) and reverse (Rev) primers, 5 mL of reverse transcriptase reaction mixture, and the LightCycler 480 (Roche Diagnostics, Rotkreuz, Switzerland), as previously described (16) . The following conditions were used: 3 mins denaturation at 95°C followed by 40 cycles at 95°C during 30 secs, and 60°C during 60 secs. All samples were analyzed in duplicate. Analyses were performed with the LightCycler 480 Software v1.5 (Roche Diagnostics, Rotkreuz, Switzerland). The expression of tested genes was normalized by that of housekeeping genes, Glyceraldehyde-3-phosphate dehydrogenase, Hypoxanthine phosphoribosyl-transferase I, and -2-microglobulin, and the geNorm program (28) . Primers were designed using the primer-BLAST software (http://www.ncbi.nlm. nih.gov/; National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD). Forward and reverse primers were designed to span at least one large intron. Primers were obtained from Eurogentec France SA (Angers, France). Primer sequences are given in Table 1 . The amplification efficiency of each target was determined using two-fold serial dilutions of pooled complementary DNA for each experiment. The polymerase chain reaction efficiency in each case was close to 100%.
Organ Culture. For short-term toxicity evaluation, spleens were aseptically removed, homogenized in saline solution, and plated. Bacterial counts were obtained by plating serial dilutions on blood agar, after 48 hrs of culture at 37°C.
Tissue Iron Determination. Tissue iron concentration was determined after tissue digestion by three different acids followed by quantification of iron using an IL test (Instrumentation Laboratory, Lexington, MA) and an Olympus AU400 automate (Chema Diagnostica, Monsano, Italy) (29) . In order to determine the effect of the iron-restricted diet on tissue iron stocks, we compared control animals receiving a normal diet (n  5) to control animals submitted to an iron poor diet.
Statistics and Data Analysis. All statistics were calculated using the Graphpad Prism v4,00 software (GraphPad Software, Inc., La Jolla, CA). Data are reported as median (interquartile range) or as percentage as appropriate. The number of observations is reported for each data and each group. Mann-Whitney tests were performed for between-group comparisons. Survival differences were determined by the Logrank test. Categorical data were compared using the Fisher's exact test. The Bonferroni correction for multiple comparisons was used for analysis of hematological parameters. All tests were twotailed. p.05 was considered significant.
RESULTS
Short-Term Pro-Oxidant Effect of
Intravenous Iron. In order to determine whether administration of intravenous iron was associated with the occurrence of oxidative stress, we assessed the activity of the phagocytes' (mainly neutrophil) nicotinamide adenine dinucleotide phosphate oxidase-2, by whole-blood chemiluminescence and the level of mRNA coding for antioxidant enzymes in the liver of control and ZIGI mice (Fig. 1) . In control mice, whole-blood chemiluminescence was higher in iron-treated than in salinetreated mice. Surprisingly, in ZIGI mice on day 5, chemiluminescence levels were similar in iron-treated and saline-treated mice (Fig. 1A) . We subsequently determined the levels of AOPP in the plasma, an indirect marker of tissue oxidative stress. AOPP levels were higher, albeit without reaching statistical significance, in control mice treated with iron than in control animals treated with saline. ZIGI mice exhibited similar levels of plasma AOPP, whether they had been treated with iron or saline (Fig. 1B) .
We subsequently determined the hepatic expression of two genes coding for enzymes implicated in detoxifying reactive oxygen species, namely superoxide dismutase 2 (sod2) and catalase. Sod2 mRNA levels were higher in iron-treated control mice than in saline-treated control animals. Conversely, iron-treated and saline-treated ZIGI mice had similar levels of expression of sod2 in the liver. Catalase expression was lower in iron-treated control mice than in saline-treated control animals. The level of expression of catalase was comparable in both groups of ZIGI mice, albeit below the level of expression of control animals (Fig. 1, C and D) . The association of higher levels of sod2 and lower levels of catalase in control mice treated by iron could lead to the excessive production of hydrogen peroxide, and thus induce oxidative stress. This unbalance was not found in ZIGI mice. Overall, intravenous iron seems to induce oxidative stress in control mice, whereas ZIGI mice seem to be protected from iron-induced oxidative stress.
Short-term Pro-Infectious Effect of Intravenous Iron.
The pro-infectious effect of iron was assessed in both the ZIGI and the septicemia mouse models (Fig. 2) . The ZIGI mouse model is considered to be due to a generalized inflammatory response, although bacterial translocation can also occur, as previously described (22) . In order to demonstrate that bacterial translocation is present but not increased after iron administration, we determined the bacterial load in the spleen of control and ZIGI mice, treated by iron or saline. None of the control mice showed evidence of bacterial translocation. ZIGI mice were associated with significant bacterial translocation. Bacterial translocation was not modified by iron administration. As a matter of fact, ZIGI mice treated by iron or saline showed a comparable percentage of spleens containing bacteria (65% and 70% respectively, p  1) and a comparable median number of bacteria per mg of spleen (p  .8, Fig. 2A) .
We then determined whether the administration of iron was associated with increased mortality rates using a mouse model of septicemia. E. coli IAI76 or IAI78 are extra-intestinal pathogenic strains with an intermediate level of virulence in the mouse model of septicemia (24) . We first tested the model in conditions of very low mortality ("nonkiller"). When iron or saline was simultaneously administered with 10 6 CFU of E. coli of the IAI78 strain, no increased mortality was induced by iron after 7 days (0% mortality in both iron-and saline-treated mice, data not shown). The same was observed when the inoculum was increased to 10 7 CFU (4% mortality for iron and saline, p  .9, Fig. 2B ). We then tested the model in conditions of intermediate mortality by simultaneously administering iron or saline and 10 8 CFU of E. coli of the IAI76 strain. No increased mortality was observed with iron in these conditions, after 7 days (32% mortality for iron vs. 44% for saline, p  .4) (Fig. 2C) .
Intravenous iron was not associated with an increased mortality in these E. coli-induced septicemia models, nor with increased bacterial translocation in the ZIGI model.
Long-Term Efficacy and Toxicity of Intravenous Iron in a Mouse Model of
Critical Care Anemia. The critical care anemia model was obtained by combining the ZIGI model with phlebotomies and by feeding the animals with a low iron diet. Control mice were also fed the iron deficient diet. Figure 3A is a schematic representation of the experimental protocol.
We confirmed that our model was a "true" model of iron deficiency by measuring hepcidin mRNA levels and iron stores in the liver and spleen.
Liver hepcidin mRNA levels on day 19 (corresponding to 7 wks of iron-restricted diet) in C, C1P1S, and C1P1I animals were undetectable confirming iron deficiency and the repression of hepcidin. Z1P1S and Z1P1I animals had low levels of hepcidin expression, but higher in Z1P1I with respectively 4.7310 Lastly, we measured liver and spleen iron contents in our animals. Control animals receiving a normal diet had higher liver and spleen iron content than control animals fed with an iron poor diet. Z1P1I animals also had higher liver and spleen iron content than Z1P1S animals (Fig. 3B) . These results confirm that 1) our model is a true iron deficiency model; and 2) the iron treatment (only) partially restore iron stores in control and ZIGI mice.
No death was recorded in the nonphlebotomized control group (C) nor in the control and phlebotomy group, whether mice had been treated by iron (C1P1I) or by saline (C1P1S). After zymosan administration and during 1-2 days, mice became lethargic, had ruffled fur, and diarrhea. In the phlebotomized ZIGI mice, 3-wk mortality rates were indistinguishable between the iron-treated (Z1P1I) and saline-treated (Z1P1S) groups (47% mortality in both groups, p  1) (Fig. 3C) .
Hematological parameters before either iron or saline administration (day 4) showed that both control and ZIGI mice were anemic and that phlebotomized ZIGI mice (Z1P) had significantly lower hemoglobin levels than phlebotomized control animals (C1P) ( Table 2) . Anemia was normocytic and poorly regenerative.
On day 19, there was a significant increase in hemoglobin levels in phlebotomized control mice treated by iron (C1P1I) compared to phlebotomized control animals treated by saline (C1P1S), although hemoglobin levels remained below that of nonphlebotomized control mice (C; Table 3 ). Iron administration to the phlebotomized ZIGI mice (Z1P1I) also raised hemoglobin levels significantly (compared to Z1P1S), although to a lesser extent than in the phlebotomized control animals (C1P1I), and was associated with a two-to three-fold increase in red blood cell number.
Overall, iron did not induce an increase in mortality rates in our mouse model of critical care anemia. In phlebotomized ZIGI mice, iron was partially effective in increasing the number of red blood cells and hemoglobin levels, even in the presence of inflammation.
DISCUSSION
In this study, we investigated efficacy as well as short-and long-term toxicity of intravenous iron in a mouse model of critical care anemia. We observed that iron induces little toxicity while being partially effective in correcting mixed, inflammatory, and iron deficiency-linked anemia in this animal model. These observations are at odds with the common thought that iron could be toxic and/or inefficient in the critical care context (30) .
Indeed, administration of iron to critically ill patients may theoretically induce two types of toxicities: 1) Labile iron may promote the formation of reactive oxygen species through the Fenton reaction; 2) Increased iron availability may promote pathogen growth and proliferation and have pro-infectious effects. The most surprising finding of this study is that iron administration in inflammatory mice induces little to no oxidative stress, compared to control mice. Furthermore, iron C1P, control mice bled by three phlebotomies; Z1P, zymosan mice bled by three phlebotomies; n.s., nonsignificant.
Values are given as median [quartile 1-quartile 3]. All mice were fed an iron poor diet starting 4 wks prior and were maintained throughout the experiment. First, we showed that, in vivo, iron activates blood neutrophils in control mice, as evidenced by increased chemiluminescence production, and moderately increases the production of protein oxidation markers. This is in accordance with several studies showing an increase in plasma oxidative stress markers following iron injections in chronic hemodialysis patients (31, 32) . Others, however, did not observe increased oxidative stress formation following iron injections in chronic hemodialysis patients (33) . We did not find any increase in chemiluminescence production in ZIGI mice. This may be due to the lower generation of labile plasma iron following iron injection in inflammatory mice. Indeed, these mice have a lower transferrin saturation (16), thereby offering a higher buffering capacity towards exogenous iron. Furthermore, macrophage activation could also increase the clearance rate of colloidal iron. Finally, the form of iron we used (ferric carboxymaltose) may be associated with a lower induction of oxidative stress (34) . We also found that iron administration induces adaptive changes in enzymes implicated in oxidative stress metabolism in the liver. In control mice, iron induced an increased expression of sod2 and a decreased expression of catalase. Sod2 catalyzes the transformation of the superoxide radical to hydrogen peroxide, whereas catalase catalyzes the transformation of hydrogen peroxide into water. Of note, messenger RNA levels of catalase and sod2 have been shown to be closely correlated with the final enzymatic activities of the respective enzymes (35) . Thus, the association of higher levels of sod2 and lower levels of catalase observed in control mice treated by iron could lead to the excessive production of hydrogen peroxide and thus induce oxidative stress. These findings have previously been reported in inflammatory situations (35) (36) (37) . The mechanism leading to a decreased expression of catalase is not clear. Catalase expression has been shown to be negatively regulated in response to cytokine stimulation such as interleukin-1, tumor necrosis factor-, and interferon-g (37). ZIGI animals did not show evidence of a change in the level of expression of catalase or sod2 after iron administration, possibly because of an earlier insult resulting in their downregulation or because of a decrease in the level of iron induced-oxidative stress. Overall, there was no evidence in favor of iron toxicity in our experiments, or in favor of its pro-infectious activity. Using two E. coli strains in a septicemia model, we have shown that intravenous iron does not increase mouse mortality. Each strain had different iron uptake and acquisition systems; the three main siderophore systems were represented in the different strains we used. The three experimental conditions that we have used mimic different pathological situations ranging from septicemia with no or very low mortality rates to septic shock associated with 30%-40% mortality rates. In addition, the ZIGI model is also partly an infectious model (22) , with bacterial translocation (i.e., positive spleen cultures, at day 5) concerning more than two thirds of the animals. We observed no increase in short-(day 5) or long-term (day 19) mortality in either the ZIGI model or our mouse model of critical care anemia. Our findings are in contradiction with those of Javadi et al (21) , where iron was administered in a model of peritonitis secondary to caecal ligation and puncture, and was associated with increased mortality rates. These differences might be explained by the fact that Javadi et al administered very high doses of iron (5 mg of iron dextrose daily during 5 days). We used an iron dosage closer to everyday clinical practice (equivalent to 15 mg/kg of ferric carboxymaltose given in a single injection). In clinical practice, several large observational studies of chronic kidney failure patients showed no link between the administration of intravenous iron and the prevalence of infection or bacteremia (38, 39) . Lastly, a recent meta-analysis including 13 randomized clinical trials did not identify any relationship between iron administration and infection (40) . Even if these studies probably do not have the power to detect differences in infection rate, they are in accordance with our results showing no increase in mortality rates when clinically relevant doses of intravenous iron are used.
Finally, we showed that intravenous iron corrected critical care anemia, at least partially. This was achieved without coadministration of erythropoiesis stimulating agents. This is in accordance with our previous work using the same animal model, showing that hepcidin synthesis is repressed and iron mobilized from tissue stores when blood withdrawal is associated to inflammation (16) . We confirmed here the repression of hepcidin synthesis by iron deficiency (or blood withdrawals), despite inflammation, as observed in other animal models (17, 18) . In a rat model, Theurl et al (17) showed that the repression of hepcidin synthesis observed in the combined situation of inflammation and blood withdrawals was associated with iron being released from macrophages. Indeed, the repression of hepcidin is necessary to iron utilization. However, the correction of anemia remains partial, probably because proinflammatory cytokines, especially interferon-g, limit the bone marrow erythroid response (41) . More importantly, in a clinical study carried out in critically ill patients, we also observed that serum hepcidin levels may be very low despite persistent inflammation (11) . It is also possible that the dose of iron we used was insufficient. The administered dosage only covered the loss of iron secondary to blood withdrawals, but did not compensate the iron deficiency due to the low iron diet. Indeed, iron stores of the animals remained low despite iron administration. Iron treatment could be of interest when true iron deficiency is associated with the anemia of inflammation (15) .
Our model has several limitations. We may not have been able to detect oxidative stress in inflammatory mice because of an incorrect timeframe, i.e., transient oxidative stress could have appeared within the 4-hr period following iron injections. Although we chose to assess neutrophil activation and AOPP levels (two makers of oxidative stress) and activation of antioxidant defense enzymes in the liver, it is possible that other biological markers of oxidative stress would have given different results. We were nonetheless able to detect an increase in oxidative stress in control animals treated by iron. Concerning the risk of iron supplementation in the context of sepsis, the ZIGI model used is not a direct infectious model and may not fully mimic the situation found in septic critically ill patients. We did, however, observe a high rate of bacterial translocation associated with the ZIGI model, and we confirmed the absence of increased mortality in the septicemia model. Finally, we used a new intravenous iron formulation, ferric carboxymaltose, which has not yet been studied to the same extent as iron sucrose. The use of this product seems to be safer and may explain some of the differences observed compared to the published literature (34) .
CONCLUSIONS
In summary, we showed that intravenous iron in a mouse model of critical care anemia is associated with little toxicity and allowed partial correction of anemia. These findings warrant clinical trials aimed at correcting anemia in the critical care setting by iron supplementation.
